Quantification of the clinical modifiers impacting high-density lipoprotein cholesterol in the community: Personalized Medicine Research Project.

High-density lipoprotein (HDL) cholesterol levels are inversely correlated with the development of cardiovascular disease. To date, genetic association studies have explained only a small proportion of the overall variance in HDL cholesterol. Further studies are needed, within practice-based cohorts, to place genetic findings into context alongside important clinical variables (eg, age, sex, body mass index, medication use, and clinical comorbidity). The Marshfield Clinic Personalized Medicine Research Project database was designed for large-scale studies of genetic epidemiology in a clinical practice-based setting. Because of its size and its unique practice-based design, this resource will provide adequate statistical power for the assessment of genetic findings related to HDL cholesterol level within the context of covariates known to modify lipid homeostasis. The authors report construction and validation of novel electronic phenotyping algorithms that can be used to model individual baseline HDL cholesterol levels within this practice-based resource. Because these algorithms were developed in a setting that reflects routine clinical care, future genetic studies using these algorithms within practice-based DNA biobanks should facilitate the identification of markers with optimal effect size after adjustment for known clinical factors contributing to the overall variance in HDL cholesterol level within the community.

[1]  M. Olivier,et al.  Comparison of linkage disequilibrium patterns between the HapMap CEPH samples and a family-based cohort of Northern European descent. , 2006, Genomics.

[2]  Dolores Corella,et al.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.

[3]  C. McCarty,et al.  Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank. , 2005, Personalized medicine.

[4]  Robert A. Hegele,et al.  Plasma lipoproteins: genetic influences and clinical implications , 2009, Nature Reviews Genetics.

[5]  V. Bittner Perspectives on dyslipidemia and coronary heart disease in women. , 2005, Journal of the American College of Cardiology.

[6]  Jocelyn Kaiser,et al.  Population Databases Boom, From Iceland to the U.S. , 2002, Science.

[7]  C. McCarty,et al.  Healthy People 2010 disease prevalence in the Marshfield Clinic Personalized Medicine Research Project cohort: opportunities for public health genomic research. , 2007, Personalized medicine.

[8]  R. Hegele,et al.  Hypertriglyceridemia: phenomics and genomics , 2009, Molecular and Cellular Biochemistry.

[9]  D. Cutler,et al.  Effect of Torcetrapib on the Progression of Coronary Atherosclerosis , 2007 .

[10]  Lisa J. Martin,et al.  Genetic determinants of obesity-related lipid traits Published, JLR Papers in Press, February 1, 2004. DOI 10.1194/jlr.M300474-JLR200 , 2004, Journal of Lipid Research.

[11]  J. Weber,et al.  Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J H Moore,et al.  The Pathway Less Traveled: Moving from Candidate Genes to Candidate Pathways in the Analysis of Genome-Wide Data from Large Scale Pharmacogenetic Association Studies. , 2008, Current pharmacogenomics and personalized medicine.

[13]  T J Cole,et al.  Smoothing reference centile curves: the LMS method and penalized likelihood. , 1992, Statistics in medicine.

[14]  P. Wilson,et al.  Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. , 1980, The American journal of cardiology.

[15]  M. McPeek,et al.  Major loci influencing serum triglyceride levels on 2q14 and 9p21 localized by homozygosity-by-descent mapping in a large Hutterite pedigree. , 2003, Human molecular genetics.

[16]  Russell A. Wilke,et al.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges , 2008, Nature Reviews Drug Discovery.

[17]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[18]  Marylyn D Ritchie,et al.  Pacific Symposium on Biocomputing--computational approaches for pharmacogenomics. , 2005, Pharmacogenomics.

[19]  M. Olivier,et al.  Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index. , 2008, Pharmacogenomics.

[20]  K. Anderson,et al.  Determinants of change in total cholesterol and HDL-C with age: the Framingham Study. , 1994, Journal of gerontology.

[21]  Peggy Peissig,et al.  The Marshfield Clinic Personalized Medicine Research Project: 2008 scientific update and lessons learned in the first 6 years. , 2008, Personalized medicine.

[22]  Richard L Berg,et al.  Use of an Electronic Medical Record for the Identification of Research Subjects with Diabetes Mellitus , 2007, Clinical Medicine & Research.

[23]  C. Ogden,et al.  Anthropometric reference data for children and adults: U.S. population, 1999-2002. , 2005, Advance data.